LAMP-2 Gene Editing via CRISPR for Danon Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Danon disease, characterized by hypertrophic/dilated cardiomyopathy, heart failure, and premature death, lacks effective therapeutics due to unclear molecular mechanisms of disease pathogenesis.
Innovation Solution
The disclosed technology involves genetic corrections of LAMP-2 mutations using CRISPR, Zinc-finger nuclease, or TALEN editing techniques to correct defective LAMP-2B-mediated autophagy in Danon disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genetic correction methods (CRISPR, Zinc-finger nuclease, or TALEN) are used to correct LAMP-2 mutations, then autophagy function is restored, but the complexity of the treatment increases
Solution Approach 1:
The patent uses guide RNA molecules as intermediaries to direct CRISPR-Cas9 nucleases to specific LAMP-2 gene sequences. The guide RNA acts as a mediator between the nuclease system and the target mutation, enabling precise genetic correction without requiring complex direct targeting mechanisms. This resolves the contradiction by providing a relatively simple RNA-based addressing system that achieves reliable gene correction.
2Reliability
If LAMP-2 mutations are corrected to restore normal autophagy, then disease progression is delayed or prevented, but the manufacturing and delivery of editing tools becomes more difficult
Solution Approach 1:
The patent segments the genetic editing system into separate functional components: CRISPR-Cas9 nucleases, guide RNA molecules, and donor DNA templates. This segmentation allows each component to be optimized and manufactured independently, then delivered separately to target cells. The modular approach simplifies manufacturing compared to delivering a single complex editing construct, and enables flexible combination of components for different LAMP-2 mutations.
3Manufacturing precision
If precise genetic editing is performed to correct LAMP-2 mutations, then autophagy-mediated cellular function is restored, but the precision requirements for targeting increase
Solution Approach 1:
The patent incorporates feedback mechanisms through guide RNA design that includes specific spacer sequences complementary to unique regions of the LAMP-2 gene. The guide RNA provides feedback control by ensuring the nuclease only binds and edits the correct target sequence through precise base-pairing. Additionally, donor DNA templates with homology arms provide feedback for accurate integration of corrected sequences, ensuring high precision in gene correction while simplifying target identification.
Data Source
AI summary
The disclosed technology includes methods of treating Danon disease, for example correcting genetic mutations in the LAMP-2 gene and ameliorating at least one Danon disease phenotype, for example defective LAMP-2B-mediated autophagy. In some implementations, the disclosed methods include editing a mutated form of the LAMP-2 gene in a patient in need thereof. In some implementations, editing the mutated form of the LAMP-2 gene may include use of a CRISPR editing technique targeted to the mutated form of the LAMP-2 gene. As a result, mutated LAMP-2 proteins in mammalian subjects may be restored in at least some of the affected cells, for example cardiomyocytes.